The Readout Loud

Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?

Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?

Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?

Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?

Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?

How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?

What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?

Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?

Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?

Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?

Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?

Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?

What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?

Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering sche...

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?

Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?